DIGITAL PATHOLOGY ASSOCIATION STANDS BEHIND THE FDA’S APPROVAL OF MARKETING WHOLE SLIDE IMAGING SYSTEM
April 13, 2017 – The Digital Pathology community is celebrating the FDA’s landmark announcement that Philips Whole Slide Imaging (WSI) system, IntelliSite, can be marketed for primary diagnosis. This technology facilitates review of digital surgical pathology slides with remote sign out capabilities, and poses a significant benefit to both pathologists and patients alike.
“The clearance for Philips IntelliSite Pathology Solution is a major milestone in pathology in the U.S. and is revolutionary in medicine,” said Esther Abels, Chair of the Regulatory Task Force with the Digital Pathology Association (DPA). “PIPS is not only developed with aim to increase efficiency and to promote collaboration, it is also the stepping stone towards computational pathology with the purpose to improve diagnostic accuracy, precision and in the end, patient care.”
Since 2013, the DPA has collaborated with the FDA to push for the adoption of WSI technology in the industry. Looking toward the future, the DPA hopes that the industry will take note of Philips’ accomplishment, and will continue to contribute to the widespread adoption of WSI technology.
“This validates the hard work of so many people who have committed time and resources to bring this technology into being,” said Eric Glassy, MD, President of the DPA. “Congratulations to the Philips team, and we hope that other vendors will quickly follow in their virtual footsteps”.
FDA Release: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm552742.htm
_____________________________________________________________________
About the Digital Pathology Association
The DPA is a not-for-profit organization comprised of pathologists, scientists, technologists and representatives from the digital pathology industry. Founded in 2009, the association’s mission is to facilitate “education and awareness of digital pathology in health care.” Its Board of Directors is composed of a mix of all segments within the digital pathology space, with both US and international representatives. Specifically, board members are users of the technology such as pathologists, histotechnologists and health information technology leaders, as well as industry members from the U.S. and abroad. Members are encouraged to share best practices and promote the use of technology amongst colleagues in order to demonstrate efficiencies, awareness and its ultimate benefits to patient care.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, imageguided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
